Evidence map›Paper›PMID 30644434›Full record

ArticleScientific reports2019

Discovering the pharmacodynamics of conolidine and cannabidiol using a cultured neuronal network based workflow.

G D C Mendis, G Berecki, E Morrisroe, S Pachernegg, M Li, M Varney, P B Osborne, C A Reid, S Halgamuge, S Petrou

Abstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. The Pharmacological Profile of Plant-Derived Cannabinoids In Vitro.Current topics in behavioral neurosciences · 2026
    Review
  2. Distinctive In Vitro Phenotypes in iPSC-Derived Neurons From Patients With Gain- and Loss-of-FunctionThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  3. Conolidine: A Novel Plant Extract for Chronic Pain.Anesthesiology and pain medicine · 2021
    Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

G D C MendisDepartment of Mechanical Engineering, University of Melbourne, Parkville, VIC, 3010, Australia.ORCID 0000-0002-0461-1605
G BereckiFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, 3010, Australia.
E MorrisroeFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, 3010, Australia.
S PacherneggFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, 3010, Australia.
M LiFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, 3010, Australia.
M VarneyNeurolixis, Inc, Dana Point, CA, 92629, USA.
P B OsborneDepartment of Anatomy and Neuroscience, University of Melbourne, Parkville, VIC, 3010, Australia.ORCID 0000-0002-8458-4159
C A ReidFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, 3010, Australia.
S HalgamugeDepartment of Mechanical Engineering, University of Melbourne, Parkville, VIC, 3010, Australia.
S PetrouFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, 3010, Australia. spetrou@unimelb.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Determining the mechanism of action (MOA) of novel or naturally occurring compounds mostly relies on assays tailored for individual target proteins. Here we explore an alternative approach based on pattern matching response profiles obtained using cultured neuronal networks. Conolidine and cannabidiol are plant-derivatives with known antinociceptive activity but unknown MOA. Application of conolidine/cannabidiol to cultured neuronal networks altered network firing in a highly reproducible manner and created similar impact on network properties suggesting engagement with a common biological target. We used principal component analysis (PCA) and multi-dimensional scaling (MDS) to compare network activity profiles of conolidine/cannabidiol to a series of well-studied compounds with known MOA. Network activity profiles evoked by conolidine and cannabidiol closely matched that of ω-conotoxin CVIE, a potent and selective Cav2.2 calcium channel blocker with proposed antinociceptive action suggesting that they too would block this channel. To verify this, Cav2.2 channels were heterologously expressed, recorded with whole-cell patch clamp and conolidine/cannabidiol was applied. Remarkably, conolidine and cannabidiol both inhibited Cav2.2, providing a glimpse into the MOA that could underlie their antinociceptive action. These data highlight the utility of cultured neuronal network-based workflows to efficiently identify MOA of drugs in a highly scalable assay.

Indexed as

AnalgesicsAnimalsCalcium Channel BlockersCalcium Channels, N-TypeCannabidiolCaveolin 2Cells, CulturedIndole AlkaloidsMiceNerve NetPrincipal Component AnalysisWorkflowAnalgesicsCalcium Channel BlockersCalcium Channels, N-TypeCannabidiolCav2 protein, mouseCaveolin 2conolidineIndole Alkaloids

Identifiers

PMID30644434
PMCPMC6333801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.